Skip to main content
. 2022 Jul 1;12:939021. doi: 10.3389/fonc.2022.939021

Figure 10.

Figure 10

The chart showed the top 15 potential drugs for NSCLC. Respectively, WH.4 (A), WZ.1.84 (B), GSK269962A (C), Gefitinib (D), EHT.1864 (E), Epothilone.B (F), Erlotinib (G), FTI.277 (H), Docetaxel (I), Bryostatin.1 (J), Bortezomib (K), BMS.754807 (L), BIRB.0796 (M), Bicalutamide (N), BI.2536 (O).